Klug entscheiden in der Inneren Medizin

Literaturnachweise

    1.
    Ibanez B, James S, Agewall S, et al.: 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018; 39: 119–77.

    2.
    Deutsch-österreichische S3-Leitlinie „Infarktbedingter kardiogener Schock – Diagnose, Monitoring und Therapie.“ AWMF-Registernummer 019–013; Entwicklungsstufe 3 (2019).

    3.
    Zeymer U, Werdan K, Schuler G, et al.: Impact of immediate multivessel percutaneous coronary intervention versus culprit lesion intervention on 1-year outcome in patients with acute myocardial infarction complicated by cardiogenic shock: Results of the randomised IABP-SHOCK II trial. Europ Heart J ACC 2017; 6: 601–9.

    4.
    de Waha S, Jobs A, Eitel I, et al.: Multivessel versus culprit lesion only percutaneous coronary intervention in cardiogenic shock complicating acute myocardial infarction: A systematic review and meta-analysis. Eur Heart J ACC 2018; 7: 28–37.

    5.
    Thiele H, Akin I, Sandri M, et al.: CULPRITSHOCK Investigators. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 2017; 377: 2419–32.

    6.
    Thiele H, Akin I, Sandri M, et al.: One year outcomes after PCI strategies in cardiogenic shock. New Engl J Med 2018; 379: 1699–710.

    7.
    Neumann FJ, Sousa-Uva M, Ahlsson A, et al.: 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87–165.

    8.
    Mehta SR, Wood DA, Storey RF.: et al, COMPLETE trial steering committee and investigators.
    Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019; 381: 1411–21.

    9.
    Ewig S, Höffken G, Kern WV, et al.: Management of adult community-acquired pneumonia and prevention – Update 2016. Pneumologie 2016; 70: 151–200.

    10.
    Ben-Ami R, Rodríguez-Baño J, Arslan H, et al.: A multinational survey of risk factors for infection with extended-spectrum betalactamase-producing enterobacteriaceae in non-hospitalized patients. Clin Infect Dis 2009; 49: 682–90.

    11.
    Creutz P, Kothe H, Braun M, et al.: Failure of ambulatory treatment in CAP patients leading to subsequent hospitalization and its association to risk factors – prospective cohort study. J Pulmon Resp Med 2013; 3:1–7.

    12.
    DGP Leitlinie zur Diagnostik, Prävention und Therapie der chronisch obstruktiven Lungenerkrankung (COPD), 24. Januar 2018, https://www.awmf.org/leitlinien/detail/ ll/020–006.html.

    13.
    Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2019 REPORT. goldcopd.org.

    14.
    Leuppi JD, Schuetz P, Bingisser R, et al.: Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease. JAMA 2013; 309: 2223–31.

    15.
    Lautz HU, Selberg O, Korber J, et al.: Protein-calorie malnutrition in liver cirrhosis. Clin Investig 1992; 70: 478–86.

    16.
    Amodio P, Bemeur C, Butterworth R, et al.: The nutritional management of hepatic encephalopathy
    in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 2013; 58: 325–36.

    17.
    European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66: 1047–81.

    18.
    Plauth M, Cabre E, Riggio O et al.: ESPEN Guidelines on Enteral Nutrition: Liver disease. Clin Nutr 2006; 25: 285–94.

    19.
    Gerbes AL, Labenz J, Appenrodt B, et al.: Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“ (AWMF 021–017). Z Gastroenterol 2019; 57: 611–80.

    20.
    Nguyen DL, Morgan T. Protein restriction in hepatic encephalopathy is appropriate for selected patients: a point of view. Hepatol Int 2014; 8: 447–51.

    21.
    Cordoba J, Lopez-Hellin J, Planas M, et al.: Normal protein diet for episodic hepatic encephalopathy:
    results of a randomized study. J Hepatol 2004; 41: 38–43.

    22.
    Campollo O, Sprengers D, Dam G et al.: Protein tolerance to standard and high protein meals in patients with liver cirrhosis. World J Hepatol 2017; 9: 667–76.

    23.
    Wijarnpreecha K1, Werlang M2, Panjawatanan P, et al.: Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis. Ann Hepatol 2019. pii: S1665–2681 (19) 32193–3.

    24.
    Mannucci PM: Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. J Thromb Haemost 2006; 4: 721–3.

    25.
    Zakeri N, Tsochatzis EA: Bleeding risk with invasive procedures in patients with cirrhosis and coagulopathy. Curr Gastroenterol Rep 2017; 19: 45.

    26.
    Grabau CM, Crago SF, Hoff LK, et al.: Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40: 484–8.

    27.
    McVay PA, Toy PT: Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31: 164–71.

    28.
    Runyon BA: Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med 1986; 146: 2259–61.

    29.
    Kurup AN, Lekah A, Reardon ST, et al.: Bleeding rate for ultrasound-guided paracentesis in thrombocytopenic patients. J Ultrasound Med 2015; 34: 1833–8.

    30.
    O’Leary JG, Greenberg CS, Patton HM, Caldwell SH: AGA clinical practice update: coagulation in cirrhosis. Gastroenterology. 2019; 157: 34–43.

    31.
    Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57: 651–3.

    32.
    Intagliata NM, Argo CK, Stine JG, et al.: Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost 2018; 118: 1491–506.

    33.
    Bundesärztekammer. Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten: mit 19 Tabellen. Dt. Ärzte-Verlag 2009.

    34.
    Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised trials. Lancet 2019; 393: 07–415.

    35.
    Han BH, Sutin D, Williamson JD et al.: Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. The ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017; 177: 955–65.

    36.
    Pilotto A, Gallina P, Panza F et al.: Rela tion of statin use and mortality in communitydwelling frail older patients with coronary artery disease. Am J Cardiol 2016; 118: 1624–30.

    37.
    Kutner JS, Blatchford PJ, Taylor DH et al.: Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting disease: a randomized trial. JAMA Intern Med 2015; 175: 691–700.

    38.
    Homes HM, Todd A: Evidence-based deprescribing of statins in patients with advanced illness. JAMA Intern Med 2015; 175: 701–2.

    Wir verwenden Cookies auf Ihrem Browser, um die Funktionalität unserer Webseite zu optimieren und den Besuchern personalisierte Werbung anbieten zu können. Bitte bestätigen Sie die Auswahl der Cookies um direkt zu der Webseite zu gelangen. Weitere Informationen finden Sie unter Datenschutz. Dort können Sie auch jederzeit Ihre Cookie-Einstellungen ändern.

    Infos
    Infos
    Mehr Info